Alamar Biosciences ALMR

NASDAQ ALMR

$30.39 -0.30 (-0.98%)

At close: Oct 26, 2026 · 4:00 PM EDT

Alamar Biosciences (ALMR) stock price is $30.39, down 0.98% on the day, as of Oct 26, 2026. It is classified in the Life Sciences Tools industry (Healthcare sector).

Key Stats

Add ratio to table…

About

Alamar Biosciences, Inc. is a commercial stage proteomics company that provides an integrated platform for protein detection and analysis. The company’s proprietary NULISA technology enables ultra sensitive detection of low abundance protein biomarkers in biological fluids such as blood. The platform combines instruments consumables and software to support research translational and potential clinical diagnostic applications. Alamar’s mission is to power precision proteomics to enable the earliest detection of disease. The NULISA assay uses a sequential capture and release chemistry that suppresses background noise and achieves attomolar level limits of detection. This capability allows measurement of targets such as brain derived phosphorylated tau 217 and neurofilament light at concentrations far below those detectable by conventional methods. The company launched its ARGO HT system in January 2024 and has since placed over one hundred instruments across more than thirty countries. The system supports high plex analysis of up to one hundred twenty proteins in a single run and can be adapted for future clinical diagnostic use.

Alamar generates revenue primarily from the sale of its ARGO HT instrument system and related consumable kits including reagents and assay panels. The company also derives income from service offerings such as its Technology Access Program instrument maintenance and training. Customers include academic research institutions biopharmaceutical companies contract research organizations and service laboratories. In the year ended December 31 2024 total revenue was twenty five point one million dollars. For the year ended December 31 2025 total revenue reached seventy four point two million dollars representing a year over year increase of ninety five percent. Gross margin improved from thirty four percent in 2024 to fifty six percent in 2025. The recurring nature of consumable sales contributes to predictable cash flow as each installed instrument generates average annual pull through of more than four hundred thousand dollars.

Alamar occupies a leading position in the proteomics market by offering a unique combination of ultra high sensitivity high specificity flexible multiplexing broad dynamic range and seamless automation through its NULISA platform. Competitors such as Olink Quanterix and traditional immunoassay providers often lack one or more of these capabilities which forces users to combine multiple technologies. Alamar’s integrated approach reduces workflow complexity and improves reproducibility giving it a distinct advantage in research and translational settings. The company’s technology is protected by a substantial patent portfolio that includes issued patents in the United States and foreign jurisdictions and pending applications covering key aspects of the NULISA assay. This intellectual property estate helps maintain barriers to entry and supports long term competitive strength. In addition Alamar has established collaborations with leading research foundations such as the Alzheimer’s Drug Discovery Foundation the Michael J Fox Foundation and the German Center for Neurodegenerative Diseases which validate its scientific approach and expand its reach in neurodegenerative disease research.

The company serves a diverse customer base that includes top global research and academic institutions leading biopharmaceutical firms contract research organizations and specialized service labs. All ten of the ten largest biopharma companies by revenue are reported as customers of Alamar. This broad base supports recurring revenue from consumable sales and opportunities for expansion into clinical diagnostics. In addition the company works with nonprofit organizations and disease foundations to develop assay panels that address unmet medical needs in areas such as Alzheimer’s disease Parkinson’s disease and various inflammatory conditions. These partnerships not only drive scientific validation but also facilitate adoption of the platform in research networks across North America Europe and Asia.

Investment Thesis

▲ Bull case

The proceeds from the upsized IPO give Alamar a strong cash position of approximately $191 million which can be deployed to accelerate research and development efforts. This capital will enable the company to broaden its assay menu beyond neurology and immunology into high growth areas such as oncology and cardiology. Expanding into these therapeutic areas opens access to larger patient populations and higher reimbursement potential. The additional funding also supports scaling manufacturing capacity for the ARGO HT system to meet rising demand from academic and clinical labs.
Alamar’s proprietary NULISA platform delivers ultra high sensitivity that can detect protein biomarkers at concentrations far below the limits of conventional assays. This technological edge allows researchers to uncover low abundance signals that are critical for early disease detection. The ability to multiplex many targets in a single run reduces sample consumption and experimental variability. These capabilities create a differentiated product that can command premium pricing and drive adoption among leading research institutions.
As of the end of 2025 the ARGO HT high throughput system had an installed base of over 100 instruments serving more than 300 customers across 25 countries. This installed base demonstrates proven market acceptance and generates a recurring revenue stream from consumables and service contracts. The geographic spread reduces reliance on any single region and provides a diversified customer footprint. Continued expansion of the installed base is expected to drive steady top line growth as each instrument generates ongoing reagent sales.
The company has already produced over 100 peer reviewed scientific articles that validate the performance of its NULISA and ARGO technologies across a range of disease models. This body of published work builds credibility with key opinion regulators and facilitates easier entry into clinical markets. Each publication acts as a marketing asset that highlights the utility of the platform for biomarker discovery. The growing literature also helps attract collaborations with pharmaceutical partners seeking companion diagnostic solutions.
Recent macroeconomic trends show de escalating geopolitical tensions have revived investor interest in new listings creating a favorable environment for life sciences IPOs. The renewed appetite for growth equities translates into higher valuation multiples for innovative biotech firms. Alamar’s successful debut with a 33% first day pop reflects strong demand from institutional and retail investors. This supportive market backdrop should make future capital raises easier and less dilutive if additional funding is required for expansion plans.

The proceeds from the upsized IPO give Alamar a strong cash position of approximately $191 million which can be deployed to accelerate research and development efforts. This capital will enable the company to broaden its assay menu beyond neurology and immunology into high growth areas such as oncology and cardiology. Expanding into these therapeutic areas opens access to larger patient populations and higher reimbursement potential. The additional funding also supports scaling manufacturing capacity for the ARGO HT system to meet rising demand from academic and clinical labs.
Alamar’s proprietary NULISA platform delivers ultra high sensitivity that can detect protein biomarkers at concentrations far below the limits of conventional assays. This technological edge allows researchers to uncover low abundance signals that are critical for early disease detection. The ability to multiplex many targets in a single run reduces sample consumption and experimental variability. These capabilities create a differentiated product that can command premium pricing and drive adoption among leading research institutions.
As of the end of 2025 the ARGO HT high throughput system had an installed base of over 100 instruments serving more than 300 customers across 25 countries. This installed base demonstrates proven market acceptance and generates a recurring revenue stream from consumables and service contracts. The geographic spread reduces reliance on any single region and provides a diversified customer footprint. Continued expansion of the installed base is expected to drive steady top line growth as each instrument generates ongoing reagent sales.
The company has already produced over 100 peer reviewed scientific articles that validate the performance of its NULISA and ARGO technologies across a range of disease models. This body of published work builds credibility with key opinion regulators and facilitates easier entry into clinical markets. Each publication acts as a marketing asset that highlights the utility of the platform for biomarker discovery. The growing literature also helps attract collaborations with pharmaceutical partners seeking companion diagnostic solutions.
Recent macroeconomic trends show de escalating geopolitical tensions have revived investor interest in new listings creating a favorable environment for life sciences IPOs. The renewed appetite for growth equities translates into higher valuation multiples for innovative biotech firms. Alamar’s successful debut with a 33% first day pop reflects strong demand from institutional and retail investors. This supportive market backdrop should make future capital raises easier and less dilutive if additional funding is required for expansion plans.

▼ Bear case

The ultra high sensitivity proteomics market remains nascent and adoption may be slower than anticipated as many laboratories continue to rely on established mass spectrometry workflows. Switching costs and validation requirements can deter customers from replacing existing platforms with a new technology. If adoption lags the company may struggle to convert its installed base into sustainable revenue growth. This risk is amplified by the long sales cycles typical in the life sciences instrument sector.
Although revenue reportedly tripled to over $74 million in 2025 the absolute figure is modest relative to the $1.5 billion market capitalization implied by the IPO price. Achieving the growth rates necessary to justify such a valuation would require revenue expansion well beyond historical trends. Failure to meet aggressive growth expectations could lead to a re rating of the stock and downward pressure on share price.
The installed base of over 100 ARGO HT instruments serves a broad but fragmented customer base of roughly 300 accounts suggesting an average selling price per instrument that may be relatively low. Low average selling price limits the upside from hardware sales and places greater reliance on consumables revenue which has yet to be demonstrated at scale. A concentration of sales among a few large accounts could expose the company to concentration risk if those customers reduce spending or switch to competitors.
Translating research use assays into clinically cleared diagnostics involves navigating complex regulatory pathways including FDA approval and reimbursement negotiations with payers. The timeline and cost associated with achieving clinical clearance are uncertain and may exceed current cash runway. Delays or setbacks in obtaining regulatory clearance would postpone the higher margin revenue streams associated with diagnostic tests and increase burn rate.
The net proceeds of approximately $191 million from the IPO may be insufficient to fund the planned expansion into oncology cardiology additional assay development and the commercial infrastructure needed for global scale. If the company needs to raise further capital soon after the IPO it could face dilution especially if market sentiment turns negative. Continued cash burn without a clear path to profitability could erode investor confidence over time.

The ultra high sensitivity proteomics market remains nascent and adoption may be slower than anticipated as many laboratories continue to rely on established mass spectrometry workflows. Switching costs and validation requirements can deter customers from replacing existing platforms with a new technology. If adoption lags the company may struggle to convert its installed base into sustainable revenue growth. This risk is amplified by the long sales cycles typical in the life sciences instrument sector.
Although revenue reportedly tripled to over $74 million in 2025 the absolute figure is modest relative to the $1.5 billion market capitalization implied by the IPO price. Achieving the growth rates necessary to justify such a valuation would require revenue expansion well beyond historical trends. Failure to meet aggressive growth expectations could lead to a re rating of the stock and downward pressure on share price.
The installed base of over 100 ARGO HT instruments serves a broad but fragmented customer base of roughly 300 accounts suggesting an average selling price per instrument that may be relatively low. Low average selling price limits the upside from hardware sales and places greater reliance on consumables revenue which has yet to be demonstrated at scale. A concentration of sales among a few large accounts could expose the company to concentration risk if those customers reduce spending or switch to competitors.
Translating research use assays into clinically cleared diagnostics involves navigating complex regulatory pathways including FDA approval and reimbursement negotiations with payers. The timeline and cost associated with achieving clinical clearance are uncertain and may exceed current cash runway. Delays or setbacks in obtaining regulatory clearance would postpone the higher margin revenue streams associated with diagnostic tests and increase burn rate.
The net proceeds of approximately $191 million from the IPO may be insufficient to fund the planned expansion into oncology cardiology additional assay development and the commercial infrastructure needed for global scale. If the company needs to raise further capital soon after the IPO it could face dilution especially if market sentiment turns negative. Continued cash burn without a clear path to profitability could erode investor confidence over time.

Peer group

Peer Comparison

Companies in the Life Sciences Tools

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	254.18 Bn	36.48	5.49	42.55 Bn
2	ABT	Abbott Laboratories	182.26 Bn	33.60	3.91	32.61 Bn
3	DHR	Danaher Corp /De/	164.19 Bn	41.01	6.54	26.56 Bn
4	ISRG	Intuitive Surgical Inc	157.75 Bn	53.34	13.62	-
5	MDT	Medtronic plc	121.22 Bn	23.17	3.23	28.15 Bn
6	SYK	Stryker Corp	117.53 Bn	31.52	4.55	14.94 Bn
7	BSX	Boston Scientific Corp	67.04 Bn	18.24	3.19	12.62 Bn
8	BDX	Becton Dickinson & Co	53.87 Bn	57.24	2.32	16.81 Bn

Alamar Biosciences ALMR

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password